Successful targeting of BRAF V600E mutation with vemurafenib in a treatment-resistant extragonadal non-seminomatous germ cell tumor

Meintker L, Haller F, Tögel L, Schmidt D, Waibel H, Mackensen A, Meidenbauer N (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 287-288

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

DOI: 10.1200/po.19.00377

Authors with CRIS profile

Lisa Meintker Department of Medicine 5 – Haematology and Oncology Florian Haller Professur für Diagnostische Molekularpathologie Lars Tögel Institute of Pathology Daniela Schmidt Medizinische Fakultät Andreas Mackensen Lehrstuhl für Innere Medizin V Norbert Meidenbauer Department of Medicine 5 – Haematology and Oncology

Additional Organisation(s)

Department of Nuclear Medicine

How to cite

APA:

Meintker, L., Haller, F., Tögel, L., Schmidt, D., Waibel, H., Mackensen, A., & Meidenbauer, N. (2019). Successful targeting of BRAF V600E mutation with vemurafenib in a treatment-resistant extragonadal non-seminomatous germ cell tumor. In ONCOLOGY RESEARCH AND TREATMENT (pp. 287-288). BASEL: KARGER.

MLA:

Meintker, Lisa, et al. "Successful targeting of BRAF V600E mutation with vemurafenib in a treatment-resistant extragonadal non-seminomatous germ cell tumor." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2019. 287-288.

BibTeX: Download